Horizon Omics Biotechnology (Changchun) Co., Ltd. was founded in August 2020 and is located in the Beihu Science and Technology Park, Changchun New Area, China. Horizon is a research-driven high-tech company, with technological innovation as the cornerstone of its development. The company boasts a multinational, high-level R&D team led by overseas PhD scientists. It is committed to developing First-in-Class and Best-in-Class novel cancer drugs, with drug targets including specially structured DNA, RNA, and their binding proteins.

      In 2021, Horizon participated in the 10th China Innovation and Entrepreneurship Competition with its "Quadruplex DNA Cancer Drug" project and won the Outstanding Award in the national competition for the Biopharmaceutical Industry. In 2022, it won the HICOOL Global Entrepreneurial Competition Excellence Award.

      In March 2021, the company received angel investment of 20 million RMB. It has since developed a series of new candidate drugs, which outperform the best drugs in the same class in terms of efficacy, metabolic stability, and toxicity data. The new drugs developed by the company will soon enter clinical trials.

      In the future, the company will continue to deepen its efforts in nucleic acid drugs, developing a series of innovative nucleic acid-targeted drugs and further expanding its pipeline. The company will also develop companion diagnostics for cancer. Additionally, it plans to establish broad collaborations with top domestic and international universities and research institutes, building a technology innovation system centered on enterprises, market-driven, and combining industry, academia, and research. The aim is to lead the new trend in drug development in China and the world.